Development of a pyrosequencing assay for rapid assessment of quinolone resistance in Acinetobacter baumannii isolates

Journal of Microbiological Methods

Volumn 86, Issue 1, 2011, Pages 115-118

  Deccache, Yann ^a   Irenge, Léonid M ^a,b   Savov, Encho ^c   Ariciuc, Mihaela ^d   Macovei, Alexandra ^d   Trifonova, Angelina ^c   Gergova, Ivanka ^c   Ambroise, Jérôme ^b   Vanhoof, Raymond ^e   Gala, Jean Luc ^a,b  

^a Defence Laboratories Department   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c MILITARY MEDICAL ACADEMY   (Bulgaria)

^d Emergency Clinical Hospital Bucharest   (Romania)

^e SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

Acinetobacter baumannii; GyrA; ParC; Pyrosequencing; Quinolone resistance

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CODON; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; NONHUMAN; PRIORITY JOURNAL; PYROSEQUENCING; QUINOLONE RESISTANCE; QUINOLONE RESISTANCE DETERMINING REGION; RELIABILITY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; BACTERIAL PROTEINS; BASE SEQUENCE; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; QUINOLINES; SEQUENCE ANALYSIS, DNA;

ACINETOBACTER BAUMANNII;

EID: 79956276122     PISSN: 01677012     EISSN: 18728359     Source Type: Journal    
DOI: 10.1016/j.mimet.2011.04.007     Document Type: Article

References (21)

1. Adams-Haduch J.M., Paterson D.L., Sidjabat H.E., Pasculle A.W., Potoski B.A., Muto C.A., Harrison L.H., Doi Y. Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob. Agents Chemother. 2008, 52:3837-3843.
2. Buirma R.J., Horrevorts A.M., Wagenvoort J.H. Incidence of multi-resistant gram-negative isolates in eight Dutch hospitals. The 1990 Dutch Surveillance Study. Scand. J. Infect. Dis. Suppl. 1991, 78:35-44.
3. Glupczynski Y., Delmee M., Goossens H., Struelens M. Distribution and prevalence of antimicrobial resistance among gram-negative isolates in intensive care units (ICU) in Belgian hospitals between 1996 and 1999. Acta Clin. Belg. 2001, 56(5):297-306.
4. Hall T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl. Acids. Symp. Ser. 1999, 41:95-98.
5. Hooper D.C. Mechanisms of fluoroquinolone resistance. Drug Resistance Update 1999, 2(1):38-55.
6. Hujer K.M., Hujer A.M., Endimiani A., Thomson J.M., Adams M.D., Goglin K., Rather P.N., Pennella T.T., Massire C., Eshoo M.W., Sampath R., Blyn L.B., Ecker D.J., Bonomo R.A. Rapid determination of quinolone resistance in Acinetobacter spp. J. Clin. Microbiol. 2009, 47(5):1436-1442.
7. Kern W.V., Andriof E., Oethinger M., Kern P., Hacker J., Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob. Agents Chemother. 1994, 38(4):681-687.
8. Lee J.K., Lee Y.S., Park Y.K., Kim B.S. Mutations in the gyrA and parC genes in ciprofloxacin-resistant clinical isolates of Acinetobacter baumannii in Korea. Microbiol. Immunol. 2005, 49:647-653.
9. Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 2008, 21:538-582.
10. Poirel L., Naas T., Nordmann P. Pyrosequencing as a rapid tool for identification of GES-type extended-spectrum beta-lactamases. J. Clin. Microbiol. 2006, 44(8):3008-3011.
11. Ronaghi M., Uhlen M., Nyren P. A sequencing method based on real-time pyrophosphate. Science 1998, 281(5375):363-365.
12. Rozen Steve, Skaletsky Helen J. Primer3 on the WWW for general users and for biologist programmers. Bioinformatics Methods and Protocols: Methods in Molecular Biology 2000, 365-386. Humana Press, Totowa, NJ. S. Krawetz, S. Misener (Eds.).
13. Saenz Y., Zarazaga M., Brinas L., Ruiz-Larrea F., Torres C. Mutations in gyrA and parC genes in nalidixic acid-resistant Escherichia coli strains from food products, humans and animals. J. Antimicrob. Chemother. 2003, 51(4):1001-1005.
14. Shah P.M., Asanger R., Kahan F.M. Incidence of multi-resistance in gram-negative aerobes from intensive care units of 10 German hospitals. Scand. J. Infect. Dis. Suppl. 1991, 78:22-34.
15. Spencer R.P., Towner K.J. Frequencies and mechanisms of resistance to moxifloxacin in nosocomial isolates of Acinetobacter baumannii. J. Antimicrob. Chemother. 2003, 52:687-690.
16. Towner K.J. Acinetobacter: an old friend, but a new enemy. J. Hosp. Infect. 2009, 73(4):355-363.
17. Van Looveren M., Goossens H. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin. Microbiol. Infect. 2004, 10(8):684-704. ARPAC Steering Group.
18. Vandercam B., Jeumont S., Cornu O., Yombi J.C., Lecouvet F., Lefevre P., Irenge L.M., Gala J.L. Amplification-based DNA analysis in the diagnosis of prosthetic joint infection. J. Mol. Diagn. 2008, 10(6):537-543.
19. Vila J., Ruiz J., Goni P., Marcos A. Jimenez de Anta M.T. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother. 1995, 39(5):1201-1203.
20. Vila J., Ruiz J., Goni P., Jimenez de Anta M.T. Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. J. Antimicrob. Chemother. 1997, 39(6):757-762.
21. Wisplinghoff H., Decker M., Haefs C., Krut O., Plum G., Seifert H. Mutations in gyrA and parC associated with resistance to fluoroquinolones in epidemiologically defined clinical strains of Acinetobacter baumannii. J. Antimicrob. Chemother. 2003, 51(1):177-180.